Vaccine design of hemagglutinin glycoprotein against influenza

Trends in Biotechnology

Volumn 29, Issue 9, 2011, Pages 426-434

  Chen, Juine Ruey ^a   Ma, Che ^a   Wong, Chi Huey ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCANS; IMMUNE RESPONSE; INFLUENZA VACCINES; INFLUENZA VIRUS; NEUTRALIZING ANTIBODIES; SURFACE GLYCOPROTEINS;

GLYCOPROTEINS; VIRUSES;

VACCINES;

INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; VIRUS LIKE PARTICLE VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FEVER; ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INJECTION SITE REACTION; MYALGIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; RHINORRHEA; SEASONAL INFLUENZA; VIRUS LIKE AGENT;

ANIMALS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RECOMBINANT PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 80051736376     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2011.04.007     Document Type: Review

References (83)

1. Girard M.P., et al. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005, 23:5708-5724.
2. Brankston G., et al. Transmission of influenza A in human beings. Lancet Infect. Dis. 2007, 7:257-265.
3. Tognotti E. Influenza pandemics: a historical retrospect. J. Infect. Dev. Ctries. 2009, 1:331-334.
4. Webster R.G., Govorkova E.A. H5N1 influenza - continuing evolution and spread. N. Engl. J. Med. 2006, 355:2174-2177.
5. Neumann G., et al. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
6. Schnitzler S., Schnitzler P. An update on swine-origin influenza virus A/H1N1: a review. Virus Genes 2009, 39:279-292.
7. Garten R.J., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) Influenza viruses circulating in humans. Science 2009, 325:197-201.
8. Pebody R.G., et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death April 2009 to March 2010. Euro. Surveill. 2010, 15:19571.
9. Kawaoka Y., Webster R.G. Interplay between carbohydrate in the stalk and the length of the connecting peptide determines the cleavability of influenza virus hemagglutinin. J. Virol. 1989, 63:3296-3300.
10. Daniels R., et al. N-Linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell 2003, 11:79-90.
11. Wang C.-C., et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18137-18142.
12. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
13. Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. 2005, 28:399-408.
14. Liao H.-Y., et al. Differential receptor binding affinities of influenza hemagglutinins on glycan arrays. J. Am. Chem. Soc. 2010, 132:14849-14856.
15. Wilson I.A., et al. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289:366-373.
16. Keil W., et al. Carbohydrates of influenza virus Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n. m. r. and methylation analysis. EMBO J. 1985, 4:2711-2720.
17. Ohuchi R., et al. Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity. J. Virol. 1997, 71:3719-3725.
18. Gallagher P.J., et al. Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus. J. Virol. 1992, 66:7136-7145.
19. Abe Y., et al. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 2004, 78:9605-9611.
20. Ohuchi M., et al. Mutations at the cleavage site of the hemagglutinin alter the pathogenicity of influenza virus a/chick/penn/83 (H5N2). Virology 1989, 168:274-280.
21. Wagner R., et al. N-Glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication. J. Gen. Virol. 2002, 83:601-609.
22. Han T., Marasco W.A. Structural basis of influenza virus neutralization. Ann. N. Y. Acad. Sci. 2011, 1217:178-190.
23. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine 2009, 27:D65-D68.
24. Wei C.J., et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med. 2010, 2. 24ra21.
25. Skehel J.J., et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:1779-1783.
26. Das S.R., et al. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010, 6:e1001211.
27. Stephenson I., Nicholson K.G. Influenza: vaccination and treatment. Eur. Respir. J. 2001, 17:1282-1293.
28. Bridges C.B., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults. JAMA 2000, 284:1655-1663.
29. Wilde J.A., et al. Effectiveness of influenza vaccine in health care professionals. JAMA 1999, 281:908-913.
30. Demicheli V., et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000, 18:957-1030.
31. Cox R.J., et al. Influenza virus: immunity and vaccination strategies Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59:1-15.
32. Treanor J.J., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
33. Belshe R.B., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 2000, 181:1133-1137.
34. Beyer W.E.P., et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 2002, 20:1340-1353.
35. Harper S.A., et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 2004, 53:1-40.
36. McCarthy M.W., Kockler D.R. Trivalent intranasal influenza vaccine, live. Ann. Pharmacother. 2004, 38:2086-2093.
37. Schultz-Cherry S., Jones J.C. Influenza vaccines: the good, the bad, and the eggs. Adv. Virus Res. 2010, 77:63-84.
38. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N. Engl. J. Med. 2010, 363:2036-2044.
39. Wei C.-J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 2008, 82:6200-6208.
40. Loeffen W.L.A., et al. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus. Vaccine 2011, 29:1545-1550.
41. Bosch B.J., et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 2010, 84:10366-10374.
42. Bright R.A., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
43. Bright R.A., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3:e1501.
44. Perrone L.A., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 2009, 83:5726-5734.
45. Aeed P.A., Elhammer A.P. Glycosylation of recombinant prorenin in insect cells: the insect cell line Sf9 does not express the mannose 6-phosphate recognition signal. Biochemistry 1994, 33:8793-8797.
46. Cox M.M.J., Hollister J.R. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37:182-189.
47. Cox M.M.J., Karl Anderson D. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir. Viruses 2007, 1:35-40.
48. Wang K., et al. Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24:2176-2185.
49. Treanor J.J., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. J. Am. Med. Assoc. 2007, 297:1577-1582.
50. Mukhopadhyay T.K. Vaccines Europe 2009. Expert Rev. Vaccines 2010, 9:125-128.
51. Cornelissen L.A.H.M., et al. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS ONE 2010, 5:e10645.
52. Bessa J., et al. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 2008, 38:114-126.
53. Rudolf M.P., et al. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 2001, 166:5917-5924.
54. Lenz P., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 2001, 166:5346-5355.
55. Kang S.-M., et al. Influenza vaccines based on virus-like particles. Virus Res. 2009, 143:140-146.
56. Tsuchiya E., et al. Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 2002, 83:1137-1146.
57. Wanzeck K., et al. Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am. J. Respir. Crit. Care Med. 2010, 183:767-773.
58. Vigerust D.J., et al. N-linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 2007, 81:8593-8600.
59. Reeves P.J., et al. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13419-13424.
60. Hanson S.R., et al. The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3131-3136.
61. Helenius A., Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 2004, 73:1019-1049.
62. de Vries R.P., et al. The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity. Virology 2010, 403:17-25.
63. Biesova Z., et al. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine 2009, 27:6234-6238.
64. Khurana S., et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010, 5:e11548.
65. Aguilar-Yáñez J.M., et al. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS ONE 2010, 5:e11694.
66. Vigerust D.J., Shepherd V.L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007, 15:211-218.
67. Okuno Y., et al. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67:2552-2558.
68. Graves P.N., et al. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126:106-116.
69. Sui J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
70. Ekiert D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
71. Throsby M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008, 3:e3942.
72. Bommakanti G., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13701-13706.
73. Eckert D.M., Kay M.S. Stalking influenza. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13563-13564.
74. Wang T.T., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18979-18984.
75. Yoshida R., et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 2009, 5:e1000350.
76. Steel J., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1. e00018-00010.
77. Wrammert J., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208:181-193.
78. Wang T.T., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6:e1000796.
79. Chen M.-W., et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13538-13543.
80. Chen M.-W., et al. Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3510-3515.
81. Harris A., et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19123-19127.
82. Xu R., et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328:357-360.
83. Brünger A.T., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 1:905-921.